We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cooling of Heart Attack Patients to Improve Recovery

By HospiMedica staff writers
Posted on 03 Oct 2003
A noninvasive cooling system that controls, monitors, and maintains the core body temperature of heart attack patients to induce mild hypothermia is designed to reduce damage to the heart. More...
The system has been cleared by the US Food and Drug Administration (FDA) for controlling body temperature in the range of 33-37o C.

Animal studies have shown that mild hypothermia may reduce the area of dead tissue and damage to the heart following a heart attack if instituted early enough and prior to reopening the diseased vessel during catheterization. The cooling is also thought to reduce the brain's need for oxygen while suppressing the chemical processes that can permanently damage brain cells in patients with sudden cardiac arrest.

The new system, called Arctic Sun, consists of a control module and energy transfer pads. The patient's current temperature and a preset target temperature provide feedback that adjusts the temperature of circulating water from the control module through the pads, based on a thermo-regulatory algorithm. Arctic Sun was developed by Medivance, Inc. (Louisville, CO, USA), which has completed a safety and feasibility study that was presented at the Transcatheter Cardiovascular Therapeutics Conference in Washington (DC, USA).

"Based on the pilot data we have reviewed, we believe that we can initiate early cooling in the emergency room, maintain patient comfort with proper medication, and achieve a below-normal therapeutic temperature target before reopening the occluded blood vessel,” said Raoul Bonan, M.D., an interventional cardiologist from the Montreal Heart Institute (Canada) who conducted the study.




Related Links:
Medivance

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.